Breast cancer: Judge stays C.R. Bard suit against Hologic over Mammosite device

February 7, 2013 by MassDevice staff

A federal judge stays a patent infringement lawsuit filed by C.R. Bard subsidiary SenoRx over Hologic's Mammosite device for treating breast cancer.

C.R. Bard

A federal judge in Delaware put a patent infringement spat between C.R. Bard subsidiary SenoRx and Hologic (NSDQ:HOLX) on hold for 90 days last week.

Judge Christopher Burke of the U.S. District Court for the Blue Hen State gave the suit, filed by SenoRx last year over Hologic's Mammosite device for treating breast cancer, ruled that a conference call slated for April 15 will go forward if the case isn't dismissed by then. Burke earlier denied a move to stay the case filed by Hologic in September 2012.

This week Hologic said the U.S. Patent & Trademark Office rejected all claims in 1 SenoRx patent in the suit and all but 4 of the other.

Sign up to get our free newsletters delivered right to your inbox.

Bedford, Mass.-based women's health company Hologic won an appeals court reversal of another case it filed against SenoRx in California in February 2011.

Bard acquired the legal matters when it spent $11 per share, or $200 million, buying SenoRx in July 2010.